Market Overview

Merck Upgraded At Credit Suisse (MRK)


Pharmaceutical Company Merck & Co. (NYSE: MRK) was upgraded at Credit Suisse (NYSE: CS) today to outperform. The analyst, Catherine Arnold, also raised her target price on the shares from $35 to $47. She cited a long-term view and said she expects "new interest to come from the pipeline." She also referenced synergies within the company and continued revenue and valuation growth.

Merck's (MRK) stock is rallying on the back of this upgrade and has appreciated over 4% today to $39.06. Year to date, shares of Merck have moved 6.79% higher. The stock has already traded 8.19 million shares versus an average of 13.44 million.

Posted-In: Upgrades Global Intraday Update Analyst Ratings


Related Articles (CS + MRK)

View Comments and Join the Discussion!

Latest Ratings

IBMWells FargoMaintains140.0
PNCWells FargoMaintains147.0
TWOUDA DavidsonMaintains17.0
IDYAOppenheimerInitiates Coverage On17.0
MBRXOppenheimerInitiates Coverage On2.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Second Day in a Row with a Lot of Damage Under the Surface

Bookkeeping: Selling Most TriQuint Semiconductor (TQNT) on Raised Guidance